We are committed to providing healthcare professionals with the information and programs that will support their efforts to treat rare, monogenic diseases of the central nervous system.
REVEAL Adolescent and Adult Trial
Taysha is evaluating the safety and preliminary efficacy of TSHA-102 in the REVEAL Adolescent and Adult Trial in Canada and the United States, a Phase 1/2 first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 in females aged 12 and older with Rett syndrome due to MECP2 loss-of-function mutation.
For more information on the REVEAL Adolescent and Adult Trial (NCT05606614), visit:
REVEAL Pediatric Trial
Taysha is evaluating the safety and preliminary efficacy of TSHA-102 in the REVEAL Pediatric Trial in the United States, United Kingdom and Canada, a Phase 1/2 first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 in pediatric females 5-8 years old with Rett syndrome due to an MECP2 loss-of-function mutation.
For more information on the REVEAL Pediatric Trial (NCT06152237), visit:
For questions about programs and clinical trials, please contact medinfo@tayshagtx.com.
At Taysha, we are focused on running well-designed clinical trials to assess the safety and efficacy of investigational therapies and provide the highest probability of bringing an approved therapy to the broader patient community. We are collaborating closely with patients, caregivers, patient organizations and medical experts to conduct clinical trials.
Expanded Access, sometimes called Managed Access, Compassionate Use, Named Patient or Early Access, is a potential pathway for a patient with an immediately life-threatening condition, serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Taysha evaluates physician requests for Expanded Access outside of a clinical study on a case-by-case basis when certain conditions are met. All Expanded Access requests must be submitted by the patient’s treating physician.
Patients or caregivers who are interested in learning more should speak with their physician. Physicians may submit questions about clinical trials and Taysha’s Expanded Access Policy to medinfo@tayshagtx.com.